Senolytics tested in RCT for osteoporosis; results not reported in abstract
The SENIOR Trial is a randomised controlled trial designed to test senolytics and antioxidant therapy for osteoporosis, framed as a disease of accelerated skeletal aging driven by senescent cell accumulation. The abstract does not report sample size, effect sizes, outcomes, or findings.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: May 11, 2026 · Discovered: Sep 16, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- Osteoporosis patients
- Primary outcome
- Effects and safety of senolytics and antioxidant therapy on bone in osteoporosis
- Effect size
- —
- Significance
- Not reported
- Journal
- Odense University Hospital
- Published
- Oct 23, 2026
Sources
Primary source
- Odense University Hospital ↗Clinical trial
Source versions
Assessment history
9/23/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.